Comparative biodistribution and safety profiling of olmesartan medoxomil oil-in-water oral nanoemulsion

Regulatory Toxicology and Pharmacology

Volumn 82, Issue , 2016, Pages 20-31

  Gorain, Bapi ^a,b   Choudhury, Hira ^a,c   Tekade, Rakesh Kumar ^d   Karan, Saumen ^a   Jaisankar, P ^e   Pal, Tapan Kumar ^a  

^a JADAVPUR UNIVERSITY   (India)

^b LINCOLN UNIVERSITY COLLEGE   (Malaysia)

^c INTERNATIONAL MEDICAL UNIVERSITY   (Malaysia)

^d NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER AHMEDABAD   (India)

^e INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

Author keywords

Brain penetration; Hematological parameters; Histopathological characteristics; Olmesartan nanoemulsion; Sub chronic toxicity; Tissue distribution

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; OLMESARTAN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BIOLOGICAL MARKER; DRUG CARRIER; EMULSION; NANOPARTICLE; OIL; WATER;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AQUEOUS SUSPENSION; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG BIOAVAILABILITY; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG MEGADOSE; DRUG SAFETY; FEMALE; FLUID INTAKE; FOOD INTAKE; HISTOPATHOLOGY; KIDNEY FUNCTION; LEUKOCYTE COUNT; LIMIT OF DETECTION; LIQUID CHROMATOGRAPHY; LIVER CELL; LIVER FUNCTION; LOW DRUG DOSE; MALE; NANOEMULSION; NONHUMAN; OIL IN WATER ORAL NANOEMULSION; ORGAN BODY WEIGHT INDEX; ORGAN WEIGHT; PHYSICAL PARAMETERS; PRIORITY JOURNAL; RAT; SUB CHRONIC TOXICITY TESTING; SUSPENSION; TANDEM MASS SPECTROMETRY; THERMOSTABILITY; THROMBOCYTE COUNT; TOXICITY TESTING; TREND STUDY; UREA NITROGEN BLOOD LEVEL; VALIDATION PROCESS; WEIGHT CHANGE; WEIGHT REDUCTION; WISTAR RAT; ANIMAL; BLOOD; BODY WEIGHT; BRAIN; CHEMISTRY; COMPARATIVE STUDY; DRINKING; DRUG EFFECTS; DRUG FORMULATION; EATING; EMULSION; METABOLISM; NANOMEDICINE; ORAL DRUG ADMINISTRATION; ORGAN SIZE; PERMEABILITY; PROCEDURES; REPRODUCIBILITY; RISK ASSESSMENT; TISSUE DISTRIBUTION;

ADMINISTRATION, ORAL; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BIOMARKERS; BODY WEIGHT; BRAIN; CHROMATOGRAPHY, LIQUID; DRINKING; DRUG CARRIERS; DRUG COMPOUNDING; EATING; EMULSIONS; MALE; NANOMEDICINE; NANOPARTICLES; OILS; OLMESARTAN MEDOXOMIL; ORGAN SIZE; PERMEABILITY; RATS, WISTAR; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; TANDEM MASS SPECTROMETRY; TISSUE DISTRIBUTION; TOXICITY TESTS, SUBCHRONIC; WATER;

EID: 84994891185     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2016.10.020     Document Type: Article

References (41)

1. Adak, M., Gupta, J.K., Acute and subacute toxicity study with hypolipidemic agent of alkyl substituted indan-1- acetic acids in mice. Res. J. Med. Med. Sci. 4 (2009), 345–350.
2. Attari, Z., Bhandari, A., Jagadish, P.C., Lewis, S., Enhanced ex vivo intestinal absorption of olmesartan medoxomil nanosuspension: preparation by combinative technology. Saudi Pharm. J. 24:1 (2016), 57–63.
3. Baboota, S., Alam, M.S., Sharma, S., Sahni, J.K., Kumar, A., Ali, J., Nanocarrier-based hydrogel of betamethasone dipropionate and salicylic acid for treatment of psoriasis. Int. J. Pharm. Investig. 1:3 (2011), 139–147.
4. Bailey, S.A., Zidell, R.H., Perry, R.W., Relationships between organ weight and body/brain weight in the rat: what is the best analytical endpoint?. Toxicol. Pathol. 32:4 (2004), 448–466.
5. Chevrier, J., Dewailly, E., Ayotte, P., Mauriege, P., Despres, J.P., Tremblay, A., Body weight loss increases plasma and adipose tissue concentrations of potentially toxic pollutants in obese individuals. Int. J. Obes. 24:10 (2000), 1272–1278.
6. Choudhury, H., Gorain, B., Chatterjee, B., Mandal, U.K., Sengupta, P., Tekade, R.K., Pharmacokinetic and Pharmacodynamic Features of Nanoemulsion Following Oral, Intravenous, Topical and Nasal Route. Curr. Pharm. Des., 2017 (Accepted article (in press).
7. Choudhury, H., Gorain, B., Paul, A., Sarkar, P., Dan, S., Chakraborty, P., Pal, T.K., Development and validation of an LC-MS/MS-ESI method for comparative pharmacokinetic study of ciprofloxacin in healthy male subjects. Drug Res. 66 (2016), 1–8, 10.1055/s-0042-116593.
8. Choudhury, H., Gorain, B., Das, A., Ghosh, B., Pal, T.K., Development and validation of a sensitive HPLC-MS/MS-ESI method for determination of febuxostat: application to pharmacokinetic study. Curr. Anal. Chem. 10 (2014), 528–536.
9. CPCSEA Guidelines for laboratory animal facility. http://icmr.nic.in/bioethics/final_cpcsea.pdf.
10. Davies, N.M., Kehoe, P.G., Ben-Shlomo, Y., Martin, R.M., Associations of anti-hypertensive treatments with Alzheimer's disease, vascular dementia, and other dementias. J. Alzheimers Dis. 26 (2011), 699–708.
11. DeMerlis, C., Goldring, J., Velagaleti, R., Brock, W., Osterberg, R., Regulatory update: the IPEC novel excipient safety evaluation procedure. Pharm. Technol. 33:11 (2009), 72–82.
12. Devalapally, H., Zhou, F., McDade, J., Goloverda, G., Owen, A., Hidalgo, I.J., Silchenko, S., Optimization of PEGylated nanoemulsions for improved pharmacokinetics of BCS class II compounds. Drug Deliv. 22:4 (2015), 467–474.
13. Food and Drug Administration of the United States. Guidance for industry Bioanalytical Method Validation. May 2001. http://www.fda.gov/downloads/Drugs/Guidances/ucm070107.pdf (accessed on: November, 2013).
14. Garcıa-Celma, M.J., Homs, M., Morales, D., Solans, C., Nano-emulsions for pharmaceutical applications. Nanocolloids: a Meeting Point for Scientists and Technologists. Chapter 11, 2016, Elsevier, 365.
15. Gera, S., Cheruvu, S., Zakkula, A., Sampathi, S., Synthesis and evaluation of olmesartan medoxomil complex with SBE7 β-CD for enhanced dissolution and bioavailability. Int. J. Pharm. Pharm. Sci. 8:1 (2015), 333–343.
16. Gorain, B., Choudhury, H., Kundu, A., Sarkar, L., Karmakar, S., Jaisankar, P., Pal, T.K., Nanoemulsion strategy for olmesartan medoxomil improves oral absorption and extended antihypertensive activity in hypertensive rats. Colloids Surf. B 115 (2014), 286–294.
17. Gorain, B., Choudhury, H., Biswas, E., Barik, A., Jaisankar, P., Pal, T.K., A novel approach for nanoemulsion components screening and nanoemulsion assay of olmesartan medoxomil through a developed and validated HPLC method. RSC Adv. 3 (2013), 10887–10893.
18. Greaves, P., Histopathology of Preclinical Toxicity Studies: Interpretation and Relevance in Drug Safety Evaluation. 2011, Academic Press.
19. Griffin, B.T., Guo, J., Presas, E., Donovan, M.D., Alonso, M.J., O'Driscoll, C.M., Pharmacokinetic, pharmacodynamic and biodistribution following oral administration of nanocarriers containing peptide and protein drugs. Adv. Drug Deliv. Rev., 2016, 10.1016/j.addr.2016.06.006 ([Epub ahead of print]).
20. Gue, E., Since, M., Ropars, S., Herbinet, R., Le Pluart, L., Malzert-Fréon, A., Evaluation of the versatile character of a nanoemulsion formulation. Int. J. Pharm. 498:1 (2016), 49–65.
21. Jaiswal, M., Dudhe, R., Sharma, P.K., Nanoemulsion: an advanced mode of drug delivery system. 3 Biotech. 5:2 (2015), 123–127.
22. Katada, E., Uematsu, N., Takuma, Y., Matsukawa, N., Comparison of effects of valsartan and amlodipine on cognitive functions and auditory P300 event-related potentials in elderly hypertensive patients. Clin. Neuropharmacol. 37:5 (2014), 129–132.
23. Kono, S., Kurata, T., Sato, K., Omote, Y., Hishikawa, N., Yamashita, T., Deguchi, K., Abe, K., Neurovascular protection by telmisartan via reducing neuro inflammation in stroke-resistant spontaneously hypertensive rat brain after ischemic stroke. J. Stroke. Cerebrovasc. Dis. 24:3 (2015), 537–547.
24. Laeis, P., Püchler, K., Kirch, W., The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction. J. Hypertens. Suppl. official J. Int. Soc. Hypertens. 19:1 (2001), S21–S32.
25. Matsumoto, S., Shimodozono, M., Miyata, R., Kawahira, K., The Angiotensin II type 1 receptor antagonist olmesartan preserves cerebral blood flow and cerebrovascular reserve capacity, and accelerates rehabilitative outcomes in hypertensive patients with a history of stroke. Int. J. Neurosci. 120:5 (2010), 372–380.
26. Morton, G.J., Meek, T.H., Schwartz, M.W., Neurobiology of food intake in health and disease. Nat. Rev. Neurosci., 15(6), 2014, 367.
27. Nakagawa, T., Hasegawa, Y., Ma, M., Kusaka, H., Lin, B., Sueta, D., Koibuchi, N., Kim-Mitsuyama, S., Abstract T MP72: mild cerebral ischemia combined with cerebral amyloid angiopathy significantly deteriorated cognitive impairment via angiotensin At1 receptor in a mouse model of Alzheimer's disease. Stroke, 46(Suppl. 1), 2015 ATMP72-.
28. Nasr, A., Gardouh, A., Ghorab, M., Novel solid self-nanoemulsifying drug delivery system (S-SNEDDS) for oral delivery of olmesartan medoxomil: design, formulation, pharmacokinetic and bioavailability evaluation. Pharmaceutics, 8(3), 2016, 20.
29. Nuffield Council on Bioethics, The Ethics of Research Involving Animals. 2005, Nuffield Council on Bioethics, London, UK (accessed: 11 April 2015) http://nuffieldbioethics.org/wp-content/uploads/The-ethics-of-research-involving-animals-full-report.pdf.
30. Organization for Economic Co-operation and Development (OECD), Guideline for the Testing of Chemicals. Guideline 407: Repeated Dose 28-day Oral Toxicity Study in Rodents. 2008, 10.1787/9789264070684-en.
31. Patel, R.P., Joshi, J.R., An overview on nanoemulsion: a novel approach. Int. J. Pharm. Sci. Res., 3(12), 2012, 4640.
32. Sengupta, P., Nandi, U., Pal, T.K., Development of safety profile evaluating pharmacokinetics, pharmacodynamics and toxicity of a combination of pioglitazone and olmesartan medoxomil in Wistar albino rats. Regul. Toxicol. Pharmacol. 62:1 (2012), 7–15.
33. Sathali, A., Jayalakshmi, J., Enhancement of solubility and dissolution rate of olmesartan medoxomil by solid dispersion technique. J. Curr. Chem. Pharm. Sci. 3:2 (2013), 123–134.
34. Sellers, R.S., Mortan, D., Michael, B., Roome, N., Johnson, J.K., Yano, B.L., Perry, R., Schafer, K., Society of Toxicologic Pathology position paper: organ weight recommendations for toxicology studies. Toxicol. Pathol. 35:5 (2007), 751–755.
35. Tota, S., Hanif, K., Kamat, P.K., Najmi, A.K., Nath, C., Role of central angiotensin receptors in scopolamine-induced impairment in memory, cerebral blood flow, and cholinergic function. Psychopharmacology 222 (2012), 185–202.
36. Tran, T.H., Li, H., Olmesartan and drug-induced enteropathy. P. T 39:1 (2014), 47–50.
37. Turner, P.V., Brabb, T., Pekow, C., Vasbinder, M.A., Administration of substances to laboratory animals: routes of administration and factors to consider. J. Am. Assoc. Lab. Anim. Sci. 50:5 (2011), 600–613.
38. Venkatasubbu, G.D., Ramasamy, S., Gaddam, P.R., Kumar, J., Acute and subchronic toxicity analysis of surface modified paclitaxel attached hydroxyapatite and titanium dioxide nanoparticles. Int. J. Nanomedicine 10:1 (2015), 137–148.
39. Villapol, S., Balarezo, M.G., Affram, K., Saavedra, J.M., Symes, A.J., Neurorestoration after traumatic brain injury through angiotensin II receptor blockage. Brain, 25, 2015 awv172.
40. Vyas, T.K., Shahiwala, A., Amiji, M.M., Improved oral bioavailability and brain transport of saquinavir upon administration in novel nanoemulsion formulations. Int. J. Pharm. 347 (2008), 93–101.
41. Yin, Q., Sun, H., Zhang, A., Wang, X., Pharmacokinetics and tissue distribution study of scoparone in rats by ultra performance liquid-chromatography with tandem high-definition mass spectrometry. Fitoterapia 83 (2012), 795–800.